FierceBiotech 2026年4月13日 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech 2026年2月28日 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival